Three Stanford scientists did not “directly participate” in a project to create the first CRISPR babies, the New York Times reports.
The context: The inquiry by Stanford University, which was first revealed by MIT Technology Review, was tasked with looking into what several high-profile faculty members knew about a project by Chinese researcher He Jiankui He to create the world’s first gene-edited babies (here is a brief summary of everything we know about that experiment so far).
The report: The university probe cleared three of its professors of wrongdoing, most notably Stephen Quake, a biophysicist who was He’s advisor when he was doing postdoctoral research at Stanford. Stanford said Quake did not directly help He with his subsequent gene-editing experiment. In a statement, the university said none of the professors had any financial or organizational ties to the work. In fact, the report claims, Quake tried to persuade He to abandon the project, and to follow proper protocols after he insisted on pursuing it.
The wider context: Since He announced the birth of the gene-edited twins Lulu and Nana in November, questions have been raised within the scientific community about who knew about the work, and what they should have done about it. Although this investigation is closed, questions over what scientists should do when confronted with ethically questionable research remain.
Sign up here to get your dose of the latest must-read news from the world of emerging tech in our daily newsletter The Download.
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
This biotech startup says mice live longer after genetic reprogramming
The result is a widely anticipated landmark for rejuvenation technology.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.